EP Patent

EP3194386A2 — Sgc stimulators

Assigned to Cyclerion Therapeutics Inc · Expires 2017-07-26 · 9y expired

What this patent protects

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, J B , n, J D , J, X, Z, Z 1 , R C1 , R C2 , Y, R 9 , o and W are as defined herein.

USPTO Abstract

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, J B , n, J D , J, X, Z, Z 1 , R C1 , R C2 , Y, R 9 , o and W are as defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3194386A2
Jurisdiction
EP
Classification
—
Expires
2017-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Cyclerion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.